<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The rate of <z:hpo ids='HP_0001297'>stroke</z:hpo> in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) depends on the presence of comorbid conditions and the use of antithrombotic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Although adjusted-dose <z:chebi fb="8" ids="10033">warfarin</z:chebi> is superior to aspirin for reducing <z:hpo ids='HP_0001297'>stroke</z:hpo> in AF, the absolute risk reduction of <z:chebi fb="8" ids="10033">warfarin</z:chebi> depends on the <z:hpo ids='HP_0001297'>stroke</z:hpo> rate with aspirin </plain></SENT>
<SENT sid="2" pm="."><plain>This prospective cohort study tested the predictive accuracy of 5 <z:hpo ids='HP_0001297'>stroke</z:hpo> risk stratification schemes </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (<z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo>, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European <z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> Trial, Primary Prevention of Arterial <z:hpo ids='HP_0001907'>Thromboembolism</z:hpo> in patients with nonrheumatic <z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> in primary care study, and <z:hpo ids='HP_0001297'>Stroke</z:hpo> Prevention and <z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> [SPAF]-III high risk or SPAF-III low risk) </plain></SENT>
<SENT sid="4" pm="."><plain>There were 207 <z:hpo ids='HP_0002140'>ischemic strokes</z:hpo> during 4887 patient-years of aspirin therapy </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> schemes predicted <z:hpo ids='HP_0001297'>stroke</z:hpo> better than chance, but the number of patients categorized as low and high risk varied substantially </plain></SENT>
<SENT sid="6" pm="."><plain>AF patients with prior <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> were classified as high risk by <z:hpo ids='HP_0000001'>all</z:hpo> 5 schemes and had 10.8 <z:hpo ids='HP_0001297'>strokes</z:hpo> per 100 patient-years </plain></SENT>
<SENT sid="7" pm="."><plain>The CHADS(2) scheme (an acronym for <z:hpo ids='HP_0001635'>Congestive heart failure</z:hpo>, <z:hpo ids='HP_0000822'>Hypertension</z:hpo>, Age &gt;75, <z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo>, and prior <z:hpo ids='HP_0001297'>Stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>) successfully identified primary prevention patients who were at high risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> (5.3 <z:hpo ids='HP_0001297'>strokes</z:hpo> per 100 patient-years) </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, patients identified as high risk by other schemes had 3.0 to 4.2 <z:hpo ids='HP_0001297'>strokes</z:hpo> per 100 patient-years </plain></SENT>
<SENT sid="9" pm="."><plain>Low-risk patients identified by <z:hpo ids='HP_0000001'>all</z:hpo> schemes had 0.5 to 1.4 <z:hpo ids='HP_0001297'>strokes</z:hpo> per 100 patient-years of therapy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Patients with AF who have high and low rates of <z:hpo ids='HP_0001297'>stroke</z:hpo> when given aspirin can be reliably identified, allowing selection of antithrombotic prophylaxis to be individualized </plain></SENT>
</text></document>